Examine the epidemiology of comorbid stimulant and OUD and related overdose risk, especially in NA/AI populations, and explore barriers patients with severe SUDs face in accessing MOUD and harm reduction services in rural areas
Summarize the pharmacology of XRBUP and its utility in increasing access to care and reducing risk of fentanyl induced respiratory depression and explore off-label, harm-reduction based approaches to utilizing XRBUP
Understand the components of low-threshold care and how it can reduce barriers to access and increase retention in treatment for patients with co-morbid stimulant and opioid use disorders